InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical...
Reports
BioAge Labs Reports Third Quarter 2025 Financial Results and Provides Business Updates
BioAge Labs, Inc. First participant dosed in Phase 1 trial of BGE-102, oral CNS-penetrant NLRP3 inhibitor, with initial SAD data...
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, Aug. 14, 2025 /PRNewswire/ -- Protalix...
Aura Biosciences Reports First Quarter 2025 Financial
First Patient Enrolled in Multi-Dose Phase 1b/2 Trial of Bel-sar in Non-Muscle-Invasive Bladder Cancer (NMIBC); Initial Data at 3 Months...
Latin America Reports’ 40 Under 40 in 2025
Coming out of the pandemic, entrepreneurship levels across Latin America and the Caribbean have led Global Entrepreneurship Monitor (GEM) to...
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
____________________1 Potential first-in-class radioenhancer “NBTXR3” was licensed to Johnson & Johnson by Nanobiotix in 2023 and renamed “JNJ-1900” for the...
